Feb 14, 2019

Drug company raises price of pain reliever by 70%

Egalet, a small pharmaceutical company, has raised the list price of its pain reliever and anti-inflammatory drug, Zorvolex, by 70%. A 90-pill bottle of Zorvolex now has a price tag of $650, compared with $383 a year ago, according to Elsevier's Gold Standard Drug Database.

The big picture: The drug does not generate a lot of relative sales, but the move is indicative of the pricing power drug companies still have, especially when drugs change ownership. The 70% price hike went into effect Feb. 1 — the day after Egalet completed its acquisition of Iroko Pharmaceuticals, the company that had owned Zorvolex.

Details: Zorvolex's new list price, which was spotted by drug pricing data firm 46brooklyn Research, does not include rebates or discounts.

  • There is little data about sales of Zorvolex, a low-dose pain reliever that received FDA approval in 2013. Iroko canceled an initial public offering that year, before sales officially started.
  • Egalet agreed to acquire Iroko last year, and the resulting company is going through the bankruptcy protection process.
  • Egalet is pushing to increase the total revenue of its 6 drugs, including Zorvolex, to at least $80 million annually.
  • A new sales team "will target pain medicine physicians, primary care physicians, nurse practitioners, orthopedic surgeons and neurologists in the United States with the intent to build awareness and increase adoption of" its drugs, according to a bankruptcy proceeding plan.

The bottom line: Egalet significantly raised the price of a brand-name drug that has generic equivalents right after it bought the drug, and as it prepares to persuade doctors to prescribe more of the drug.

  • Egalet did not respond to multiple phone calls and emails.

Go deeper

Trump says he will campaign against Lisa Murkowski after her support for Mattis

Trump with Barr and Meadows outside St. John's Episcopal church in Washington, D.C. on June 1. Photo: Brendan Smialowski/AFP via Getty Images

President Trump tweeted on Thursday that he would endorse "any candidate" with a pulse who runs against Sen. Lisa Murkowski (R-Alaska).

Driving the news: Murkowski said on Thursday that she supported former defense secretary James Mattis' condemnation of Trump over his response to protests in the wake of George Floyd's killing. She described Mattis' statement as "true, honest, necessary and overdue," Politico's Andrew Desiderio reports.

8 hours ago - World

The president vs. the Pentagon

Trump visits Mattis and the Pentagon in 2018. Photo: Brendan Smialowski/AFP via Getty

Over the course of just a few hours, President Trump was rebuffed by the Secretary of Defense over his call for troops in the streets and accused by James Mattis, his former Pentagon chief, of trampling the Constitution for political gain.

Why it matters: Current and former leaders of the U.S. military are drawing a line over Trump's demand for a militarized response to the protests and unrest that have swept the country over the killing of George Floyd by police.

New York Times says Tom Cotton op-ed did not meet standards

Photo: Avalon/Universal Images Group via Getty Images)

A New York Times spokesperson said in a statement Thursday that the paper will be changing its editorial board processes after a Wednesday op-ed by Sen. Tom Cotton (R-Ark.), which called for President Trump to "send in the troops" in order to quell violent protests, failed to meet its standards.

Why it matters: The shift comes after Times employees began a coordinated movement on social media on Wednesday and Thursday that argued that publishing the op-ed put black staff in danger. Cotton wrote that Trump should invoke the Insurrection Act in order to deploy the U.S. military against rioters that have overwhelmed police forces in cities across the country.